BI-6015 is primarily explored for its potential in cancer therapy, particularly in targeting specific pathways involved in tumor growth and progression. It functions as an inhibitor of proteins such as ID1 and ID3 that play a critical role in cancer cell survival, proliferation, and metastasis. Research indicates its application in preclinical studies to evaluate its efficacy in reducing tumor size and inhibiting metastasis. Additionally, BI-6015 is being investigated for its ability to enhance the effectiveness of existing chemotherapy agents, potentially offering a synergistic approach to cancer treatment. Its targeted mechanism of action may also help minimize adverse effects commonly associated with conventional therapies. Furthermore, ongoing studies assess its side effects and toxicity to ensure safe use in humans, making it a promising candidate for further development in oncology.